Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.
Diana M SobierajBrandon K MartinezAdrian V HernandezCraig I ColemanJoseph S RossKarina M BergDavid C SteffensWilliam L BakerPublished in: Journal of the American Geriatrics Society (2019)
In patients 65 years of age or older with MDD, treatment of the acute phase of MDD with SNRIs, but not SSRIs, was associated with a statistically greater number of overall adverse events vs placebo. SSRIs and SNRIs led to a greater number of study withdrawals due to adverse events vs placebo. Duloxetine increased the risk of falls that as an outcome was underreported in the literature. Few studies examined head-to-head comparisons, most trials were not powered to evaluate adverse events, and results of observational studies may be confounded. Comparative long-term studies reporting specific adverse events are needed to inform clinical decision making regarding choice of antidepressants in this population. J Am Geriatr Soc 67:1571-1581, 2019.
Keyphrases
- major depressive disorder
- decision making
- end stage renal disease
- physical activity
- ejection fraction
- newly diagnosed
- systematic review
- optic nerve
- prognostic factors
- case control
- double blind
- bipolar disorder
- peritoneal dialysis
- community dwelling
- emergency department
- randomized controlled trial
- clinical trial
- phase iii
- middle aged
- patient reported outcomes
- combination therapy
- light emitting